Bilici, A. Et Al. 2022. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (ELECTR NETWORK).

Bilici, A., Olmez, O. F., Sezer, A., Oksuzoglu, B., Kaplan, M. A., Karadurmus, N., ... Cubukcu, E.(2022). Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK, 2022

Bilici, A. Et Al. (2022) . "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={Ahmet Bilici Et Al. }, title={Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={}, country={ELECTR NETWORK}, year={2022}}